November 18, 2013

Sanofi Discontinues Clinical Development of Investigational JAK2 Agent Fedratinib (SAR302503)

 

Sanofi Discontinues Clinical Development of Investigational JAK2 Agent Fedratinib (SAR302503)

Paris, France – November 18, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the decision to halt all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor, fedratinib (SAR302503).